bullish
Shanghai Henlius Biotech (2696.HK) Privatization Update - Some New Information Worth the Attention
495 Views10 Sep 2024 08:55
Fosun Pharma will make every effort to promote the success of privatization due to plans for Henlius internal integration with Fosun Pharma and future re-listing. The Cash Alternative is better choice
What is covered in the Full Insight:
- Privatization Update
- Henlius' Financial Performance
- Future Revenue and Profit Projections
- Fosun Pharma's Challenges
- Merger and Future Strategy
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 3-minute read)
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
Price Chart(Sign Up to Access)
- China Healthcare Weekly (Sep29)- Henlius Privatization Update, NHSA Fee Control, Hansoh Is Exception29 Sep 2024
- Pre-IPO Carote Ltd (PHIP Updates) - High Performance Growth May Not Be Sustainable19 Sep 2024
- Akeso Biopharma Inc (9926 HK) - Something Beautiful Is Happening11 Sep 2024
- CPMC Holdings (906.HK) Privatization Update - ORG Is Pushing Baosteel to Raise Its Offer02 Sep 2024
- Shanghai Henlius Biotech (2696.HK) - Privatization Has Taken a Positive Step Forward26 Aug 2024
- Fosun Pharma (2196 HK/600196.CH) To Privatize Henlius (2696.HK) - Things Are Not as Good as Expected03 Jun 2024
x